Top 7 China Gene Editing CRISPR Companies 2025
China has emerged as a global hub for CRISPR gene editing research and commercialization, with over 200 companies and research institutions actively developing gene editing therapies. The country's CRISPR sector benefits from strong government funding, a large patient population for clinical trials, and growing regulatory clarity around gene therapy approvals. Chinese researchers have published over 10,000 CRISPR-related papers and filed thousands of patents, making China second only to the United States in gene editing innovation. The sector is moving rapidly from laboratory research to clinical trials and commercial products.
BeiGene (百济神州)
Revenue: $2.5B+ (2024)
BeiGene is China's largest biotech company by revenue, integrating CRISPR gene editing into its oncology drug discovery pipeline. The company uses CRISPR screening to identify drug targets and develop engineered cell therapies. BeiGene's Brukinsa (zanubrutinib) has become a global blockbuster cancer drug. The company's gene editing capabilities support its expanding CAR-T and TCR therapy programs targeting hematological malignancies and solid tumors.
Bioray Laboratories (博瑞生物)
CRISPR-edited crops: 15+
Bioray Laboratories specializes in agricultural gene editing using CRISPR-Cas9 to develop improved crop varieties. The company has created CRISPR-edited rice, wheat, soybean, and corn strains with enhanced yield, disease resistance, and stress tolerance. Unlike transgenic GMO crops, Bioray's gene-edited products face a more favorable regulatory pathway in China, where gene-edited crops without foreign DNA are treated differently from traditional GMOs.
GenScript (金斯瑞)
CRISPR services: 10,000+ projects
GenScript is a global biotechnology company providing CRISPR gene editing tools, custom cell engineering services, and gene synthesis platforms to researchers and pharmaceutical companies worldwide. The company's CRISPR service portfolio includes gRNA design, donor DNA synthesis, cell line engineering, and in vivo CRISPR delivery solutions. GenScript's subsidiary Legend Biotech developed Carvykti, an approved CAR-T therapy for multiple myeloma.
Innovent Biologics (信达生物)
Revenue: $1B+ (2024)
Innovent Biologics has integrated gene editing technology into its cell therapy development programs, including CRISPR-engineered CAR-T cells with enhanced persistence and reduced immunogenicity. The company's research platform combines CRISPR screening with its existing antibody drug capabilities to develop next-generation cancer immunotherapies. Innovent has multiple gene-edited cell therapy candidates in preclinical and early clinical development.
Legend Biotech (传奇生物)
CAR-T therapy: Carvykti approved
Legend Biotech, a GenScript subsidiary, developed Carvykti (ciltacabtagene autoleucel), a BCMA-targeted CAR-T therapy approved for multiple myeloma in the US, EU, Japan, and China. The company is advancing next-generation cell therapies incorporating gene editing to improve CAR-T cell persistence, reduce manufacturing costs, and expand into solid tumors. Legend's partnership with Johnson & Johnson provides global commercialization capabilities.
Cure Genetics (邦耀生物)
Clinical trials: 5+
Cure Genetics is a Shanghai-based gene editing biotech company developing base editing and CRISPR-Cas9 therapies for genetic diseases and cancer. The company's lead programs target beta-thalassemia, sickle cell disease, and certain cancers. Cure Genetics has developed proprietary base editing platforms with improved precision and reduced off-target effects, positioning it as a leading Chinese innovator in next-generation gene editing therapeutics.
Chimege Therapeutics (邦耀/引加生物)
Platform: Base editing + prime editing
Chimege Therapeutics focuses on developing base editing and prime editing technologies for therapeutic applications. The company has built proprietary delivery systems for in vivo gene editing targeting liver diseases, muscular disorders, and neurological conditions. Chimege collaborates with leading Chinese hospitals to conduct clinical research and has established partnerships with international pharma companies for co-development of gene editing therapies.
Comparison Table
| Company | Focus Area | Key Metric | CRISPR Application | Clinical Stage | Revenue | Global Presence |
|---|---|---|---|---|---|---|
| BeiGene | Oncology | $2.5B+ revenue | Target discovery | Phase 3 | Global | 30+ countries |
| Bioray | Agriculture | 15+ crops | Crop improvement | Field trials | Agriculture | China |
| GenScript | Tools/services | 10K+ projects | Platform provider | N/A | $500M+ | Global |
| Innovent | Cell therapy | $1B+ revenue | CAR-T editing | Phase 1/2 | China | Primarily China |
| Legend Biotech | CAR-T therapy | Carvykti approved | Cell engineering | Approved | $1B+ | Global |
| Cure Genetics | Base editing | 5+ trials | Therapeutic editing | Phase 1 | Startup | China |
| Chimege | Multi-modal editing | Base + prime | Therapeutic delivery | Preclinical | Startup | China |
Frequently Asked Questions
How advanced is China's CRISPR gene editing industry?
China has the world's second-largest CRISPR research ecosystem, with 50+ ongoing clinical trials, 10,000+ published papers, and thousands of patents. Chinese scientists were among the first to use CRISPR in human embryos (2015) and have since made major contributions to base editing, prime editing, and in vivo delivery. The sector benefits from government funding exceeding ¥10 billion and a large patient population enabling rapid clinical trial enrollment.
Has China approved any CRISPR gene therapies?
As of 2025, China has approved gene therapy products (including CAR-T therapies like Fucaso and Carvykti from Legend Biotech) but has not yet approved a standalone CRISPR-based gene editing therapy. However, multiple CRISPR clinical trials are in progress for beta-thalassemia, sickle cell disease, and various cancers. Regulators have established clear pathways for gene editing therapy review, and first approvals are expected within 1-2 years, following the lead of Casgevy approvals in the US and UK.
What is China's regulatory stance on gene editing?
China permits therapeutic gene editing under strict regulatory oversight by the NMPA (National Medical Products Administration). Clinical gene editing trials require institutional review board approval and NMPA filing. Heritable germline editing remains prohibited. Agricultural gene editing is regulated separately, with gene-edited crops (no foreign DNA inserted) facing streamlined approval compared to traditional GMOs. China has also established ethical guidelines and safety monitoring frameworks for gene editing research.
How does Chinese CRISPR compare to global competitors?
Chinese CRISPR research is highly competitive globally, particularly in base editing, agricultural applications, and clinical trial volume. China lags behind the US in commercial product approvals and foundational IP ownership (Broad Institute patents). However, Chinese companies are rapidly closing the gap with innovative delivery technologies, novel Cas enzyme variants, and cost-effective manufacturing. Academic-industry collaboration is strong, with institutions like CAS, Tsinghua, and Peking University producing world-class research.
What are China's strengths in agricultural gene editing?
China leads the world in CRISPR applications for agriculture, with major programs developing gene-edited rice (increased yield, pest resistance), wheat (disease resistance, quality improvement), soybeans (oil content optimization), and pigs (disease resistance, lean meat). Companies like Bioray and public research institutions have created gene-edited varieties approaching commercial approval. China's favorable regulatory environment for gene-edited crops (without foreign DNA) positions it to potentially lead global adoption of gene-edited food.